About JSR Life Sciences
Learn what we are all about
JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers.
JSR supports the drug discovery and development needs of our partners with tailored solutions that identifies and applies the right tools and technologies to support their unique therapeutic programs. From de-risking molecule selection and accelerating biologic development timelines, to increasing clinical success rates and developing in vitro diagnostics, JSR Life Sciences is committed to guiding our customers’ innovative science along the path to becoming life-saving medicines.
Accelerating Our Life Sciences Footprint
We offer our partners best-in-class research products and services for outsourced drug discovery and development. With our proprietary products and services and through our affiliate companies, JSR has a global presence including 28 sites in seven countries.
We leverage the core competencies of our affiliates to create integrated solutions that are designed to guide our partners’ programs from the lab through commercialization.
Contract research organization with advanced technology for precision medicine
Cell line development with best-in-class modular technology and specialized solutions
Biomarker discovery for companion and in vitro diagnostics
Global contract development and manufacturing organization with advanced analytical capabilities
JSR’s specialty life science research products include:
Amsphere A3, a protein A chromatography resin for advanced protein separation
ChromNeX chromatography platform for improved purification processes
Magnosphere hydrophilic and hydrophobic microparticles for research and in vitro diagnostics use
JSR Life Sciences is a business unit of JSR Corporation, a multinational advanced materials and solutions company based in Japan.
Latest JSR Life Sciences news
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...
The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.